21358-13-4

Usage

InChI:InChI=1/C15H13N3OS/c20-15-17-16-14(11-19-13-9-5-2-6-10-13)18(15)12-7-3-1-4-8-12/h1-10H,11H2,(H,17,20)

Upstream product

• 4664-55-5 phenoxyacetyl hydrazine 
• 18233-67-5 2-(2-phenoxyacetyl)-N-phenylhydrazinecarbothioamide 
• 2555-49-9 phenoxyacetic acid ethyl ester 
• 103-72-0 phenyl isothiocyanate 
• 122-59-8 2-phenoxyacetic acid 

Downstream Products

• 129544-79-2 1-(5-Phenoxymethyl-4-phenyl-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-1H-benzotriazole 
• 1240489-61-5 3-(3,4-dichlorobenzylsulfanyl)-5-phenoxymethyl-4-phenyl-4H-1,2,4-triazole 
• 1240489-60-4 3-(2,4-dichlorobenzylsulfanyl)-5-phenoxymethyl-4-phenyl-4H-1,2,4-triazole 
• 956085-82-8 1-(4-nitrophenyl)-2-[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-ylsulfanyl]ethanone 
• 335219-32-4 C₁₈H₁₉N₃OS 
• 131142-17-1 ethyl [3-phenoxymethyl-4-phenyl-1,2,4-triazole-5-yl-thio]acetate 
• 1418012-84-6 C₁₈H₁₉N₃O₂ 
• 1418012-76-6 C₂₁H₁₇N₃OS 
• 1418012-86-8 C₂₁H₂₃N₃O₂ 
• 1418012-85-7 C₂₀H₂₁N₃O₂ 
• 1418012-82-4 C₁₈H₁₉N₃O₃S 
• 1418012-81-3 3-methanesulfonyl-5-phenoxymethyl-4-phenyl-4H[1,2,4]triazole 
• 1418012-83-5 C₁₅H₁₃N₃O 
• 129544-85-0 MIND₄-19 

Relevant academic research and scientific papers

1,2,4-Triazole-based benzothiazole/benzoxazole derivatives: Design, synthesis, p38α MAP kinase inhibition, anti-inflammatory activity and molecular docking studies

Novel N-(benzothiazol/oxazol-2-yl)-2-[(5-(phenoxymethyl)-4-aryl-4H-1,2,4-triazol-3-yl)thio] acetamide derivatives (5a-n) were synthesized and investigated for in vitro anti-inflammatory activity and p38α MAP kinase inhibition. Compounds showing good in vitro activities (5a, 5b, 5d, 5e, 5i, 5k and 5l) were studied for their in vivo anti-inflammatory activity using carrageenan induced rat paw edema model. Compound 5b emerged as the most active compound with an edema inhibition of 84.43%. It also showed improved GI safety profile with lower ulcer severity index and lipid peroxidation potential. Also, p38α MAP kinase assay of 5b showed superior inhibitory potency (IC50:0.031 ± 0.14 μM) than the standard SB 203580 (IC50:0.043 ± 0.14 μM). To predict their binding mode compounds were also docked against p38α MAP kinase enzyme. Compound 5b and SB 203580 showed hinge region interaction with MET 109.

Alkylsulfanyl-1,2,4-triazoles, a New Class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships

Valosine containing protein (VCP), also known as p97, is a member of AAA ATPase family that is involved in several biological processes and plays a central role in the ubiquitin-mediated degradation of misfolded proteins. VCP is an ubiquitously expressed, highly abundant protein and has been found overexpressed in many tumor types, sometimes associated with poor prognosis. In this respect, VCP has recently received a great deal of attention as a potential new target for cancer therapy. In this paper, the discovery and structure-activity relationships of alkylsulfanyl-1,2,4-triazoles, a new class of potent, allosteric VCP inhibitors, are described. Medicinal chemistry manipulation of compound 1, identified via HTS, led to the discovery of potent and selective inhibitors with submicromolar activity in cells and clear mechanism of action at consistent doses. This represents a first step toward a new class of potential anticancer agents.

Synthesis of 1,2,4-triazole-3-thiols and their S-substituted derivatives

New 1,2,4-triazole-3-thiols were synthesized by reactions of the corresponding carboxylic acid hydrazides with isothiocyanates and subsequent cyclization of intermediate 1,4-substituted thiosemicarbazides. Alkylation of 1,2,4-triazole-3-thiols with benzyl

Synthesis and biological activity of new derivatives of 3-phenoxymethyl-4-R-D2-1,2,4-triazoline-5-thione.

New derivatives of 1,2,4-triazoline-5-thione system were obtained. The effects of both these compounds AP-I (3-phenoxymethyl-4-phenyl-D2-1,2,4-triazoline-5-thione) and AP-II (3-phenoxymethyl-4-ethyl-D2-1,2,4-triazoline-5-thione) on the central nervous sys

USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO)

There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.